Our results suggest that two circulating peptides derived from C3f, a substrate of MMP-9 in the tumor microenvironment, reflect the content of MMP-9 in tumors, and consequently indicate the therapeutic efficacy (i.e., treatment with EphA2-siRNA). The gene discussed is LPCAT3; the disease is neoplasm.